BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ortega VE, Li X, O'Neal WK, Lackey L, Ampleford E, Hawkins GA, Grayeski PJ, Laederach A, Barjaktarevic I, Barr RG, Cooper C, Couper D, Han MK, Kanner RE, Kleerup EC, Martinez FJ, Paine R 3rd, Peters SP, Pirozzi C, Rennard SI, Woodruff PG, Hoffman EA, Meyers DA, Bleecker ER; NHLBI Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS). The Effects of Rare SERPINA1 Variants on Lung Function and Emphysema in SPIROMICS. Am J Respir Crit Care Med 2020;201:540-54. [PMID: 31661293 DOI: 10.1164/rccm.201904-0769OC] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. The Lancet 2022. [DOI: 10.1016/s0140-6736(22)00470-6] [Reference Citation Analysis]
2 Zhang Q, Li W, Ayidaerhan N, Han W, Chen Y, Song W, Yue Y. IP3 R attenuates oxidative stress and inflammation damage in smoking-induced COPD by promoting autophagy. J Cell Mol Med 2021. [PMID: 34060199 DOI: 10.1111/jcmm.16546] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Bellemare J, Gaudreault N, Valette K, Belmonte I, Nuñez A, Miravitlles M, Maltais F, Bossé Y. The Clinical Utility of Determining the Allelic Background of Mutations Causing Alpha-1 Antitrypsin Deficiency: The Case with the Null Variant Q0(Mattawa)/Q0(Ourém). Chronic Obstr Pulm Dis 2021;8. [PMID: 33150777 DOI: 10.15326/jcopdf.8.1.2020.0168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lackey L, Coria A, Ghosh AJ, Grayeski P, Hatfield A, Shankar V, Platig J, Xu Z, Ramos SBV, Silverman EK, Ortega VE, Cho MH, Hersh CP, Hobbs BD, Castaldi P, Laederach A. Alternative poly-adenylation modulates α1-antitrypsin expression in chronic obstructive pulmonary disease. PLoS Genet 2021;17:e1009912. [PMID: 34784346 DOI: 10.1371/journal.pgen.1009912] [Reference Citation Analysis]
5 Barjaktarevic I, Miravitlles M. Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis. BMC Pulm Med 2021;21:99. [PMID: 33757485 DOI: 10.1186/s12890-021-01466-x] [Reference Citation Analysis]
6 Ruiz-Duque B, Bañuls L, Reinoso-Arija R, Carrasco-Hernandez L, Caballero-Eraso C, Dasí F, Lopez-Campos JL. Methodologies for the Determination of Blood Alpha1 Antitrypsin Levels: A Systematic Review. J Clin Med 2021;10:5132. [PMID: 34768650 DOI: 10.3390/jcm10215132] [Reference Citation Analysis]
7 Franciosi AN, Hobbs BD, McElvaney OJ, Molloy K, Hersh C, Clarke L, Gunaratnam C, Silverman EK, Carroll TP, McElvaney NG. Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med 2020;202:73-82. [PMID: 32197047 DOI: 10.1164/rccm.202002-0262OC] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
8 Sandford AJ. Alpha-1 Antitrypsin Mutations: Is One Too Many? Am J Respir Crit Care Med 2020;201:505-6. [PMID: 31810377 DOI: 10.1164/rccm.201911-2209ED] [Reference Citation Analysis]
9 Ghosh AJ, Hobbs BD. Recent advancements in understanding the genetic involvement of alpha-1 antitrypsin deficiency associated lung disease: a look at future precision medicine approaches. Expert Rev Respir Med 2022;:1-10. [PMID: 35025710 DOI: 10.1080/17476348.2022.2027755] [Reference Citation Analysis]